Log In
BCIQ
Print this Print this
 

GALNS Enzyme Replacement Therapy

  Manage Alerts
Collapse Summary General Information
Company Vivendy Therapeutics Ltd.
DescriptionRecombinant human fusion protein containing a peptide sequence of 4-15 amino acids attached at the N terminus of the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) enzyme
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis IVA (MPS IVA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today